RIDA®QUICK ADM Monitoring is a rapid test for adalimumab drug concentration monitoring which supports timely dose adjustments in clinical practice. A poster about the validation of the test was presented at the UEGW 2018 in Vienna.
The RIDA®QUICK ADM Monitoring is intended for the measurement of adalimumab in serum and plasma of patients with inflammatory diseases. In this poster presentation, the authors, in collaboration with KU Leuven, highlighted the excellent accuracy and precision of the RIDA®QUICK ADM Monitoring and its interchangeability with the conventional ELISA technique. Its single sample analysis and rapid test turn-around (only 20 minutes) offer great advantages for daily routine clinical practice, supporting timely dose adjustments of patients receiving adalimumab therapy.
